Acetylon Pharmaceuticals Secures $15,000,000 New Round

  • Feed Type
  • Date
    2/9/2012
  • Company Name
    Acetylon Pharmaceuticals
  • Mailing Address
    70 Fargo Street Boston, MA 02210
  • Company Description
    Acetylon Pharmaceuticals is a Boston-based company recently formed to commercialize promising pharmaceutical technology emerging from collaborative research at Harvard University and the Dana-Farber Cancer Institute. Acetylon intends to pursue the clinical development and commercialization of next generation, selective, small-molecule Histone Deacetylase (HDAC) inhibitors with enhanced therapeutic effectiveness and tolerability versus current alternatives.
  • Website
    http://www.acetylon.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $15,000,000
  • Transaction Round
    Undisclosed
  • Proceeds Purposes
    Acetylon’s scientists plan to test ACY-1215 in combination with bortezomib (Velcade), made by Millennium Pharmaceuticals.
  • M&A Terms
  • Venture Investor
    Celgene Corporation

Trending on Xconomy